Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.08, Zacks reports.
Spyre Therapeutics Stock Down 8.9 %
Shares of SYRE traded down $1.76 during trading hours on Monday, hitting $17.94. The company had a trading volume of 526,644 shares, compared to its average volume of 552,713. The business has a fifty day moving average of $22.36 and a 200-day moving average of $26.82. The firm has a market cap of $922.67 million, a price-to-earnings ratio of -2.40 and a beta of 2.85. Spyre Therapeutics has a 12 month low of $17.55 and a 12 month high of $47.97.
Analyst Ratings Changes
Several research firms recently issued reports on SYRE. Robert W. Baird upped their target price on Spyre Therapeutics from $50.00 to $65.00 and gave the stock an "outperform" rating in a report on Wednesday, November 13th. Wedbush reiterated an "outperform" rating and set a $65.00 price objective on shares of Spyre Therapeutics in a research note on Monday, January 13th. Finally, The Goldman Sachs Group raised Spyre Therapeutics to a "strong-buy" rating in a report on Tuesday, February 18th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $54.83.
Check Out Our Latest Report on SYRE
About Spyre Therapeutics
(
Get Free Report)
Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).
See Also
Before you consider Spyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spyre Therapeutics wasn't on the list.
While Spyre Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
